Exact Sciences Investor Presentation — December 2021

Document content

Exact Sciences (EXAS)

Healthcare / Diagnostics & ResearchStock Rover

Stock Report | December 05, 2021

$76.59 -$3.98 (-4.94% )as of Friday's close

$74.58 $159.54Cap ($M USD)

EXAS has underperformed the S&P

500 by -63.9% in the past year .

EXAS has underperformed its sector

by -53.3% in the past year .

The Healthcare sector has

underperformed the market by

-10.6% in the past year .

Strong BuyThe consensus rating has worsened a little

since last month when it was also Strong Buy .

BuyBuy Hold SellStrong

Fair V alue - Uncertain

 Margin of Safety 29%The Margin of Safety is the dif ference

between a company's Fair V alue and the

current price. See more on page 8. 6 warnings 

62Value Score: Our value score looks at EV/EBITDA,

P/E, P/S, P/TB (Price/T angible Book) and EPS

Predictability . P/S and P/TB are compared within a

sector . Other metrics are compared across all stocksQuality

46Quality Score: Our quality score compares

profitability and balance sheet metrics to find high

quality companies using ROIC, Net Margin, Gross

Margin, Interest Coverage, and Debt / Equity metrics.

47Growth Score: Our growth score looks at the 5 year

history and the forward estimates for EBITDA, Sales,

and EPS growth, ranking the best companies across